Hot or Not, Stock Market Edition: 10/06/2026

Happy Tuesday. Here's what the Zen Ratings are fueling up and running out of gas on today:

• Hot: Oil and gas giant Petrobras (PBR) is drilling up discoveries and a unanimous Strong Buy; steelmaker Nucor (NUE) is forging real momentum
• Not: Hydrogen fuel cell player Plug Power (PLUG) can't get the current flowing; biotech name Viking Therapeutics (VKTX) is burning cash faster than it raises it

P.S. Want more timely hot stock picks? Start here. 

A note from our sponsors...

The ONLY AI opportunity you should be looking at

This is the ONLY AI wealth-building opportunity you should be watching right now.

No. It's not about Nvidia, Tesla, or Meta...

It's about one overlooked company profiting off AI "digital goldmines" that are poised to experience 100x growth very soon.

This new opportunity will change the market and make investors a lot of money.

That's why it has received a $500 billion commitment from President Trump himself...

Learn more about this little-known company here >>>

🔥 HOT: Brazilian oil giant Petrobras (PBR) just delivered a string of fresh catalysts: a new offshore oil discovery, a 22-year LNG deal with Cheniere, and expansion into new African blocks. Profit margins have also jumped sharply over the past year. For investors, that means growth in reserves and long-term supply at the same time, while the stock still trades at a single-digit earnings multiple. At writing, shares have nearly doubled from their 52-week low and sit close to their high, but valuation remains inexpensive and the dividend yield is still attractive.

PBR has a Zen Rating of A, a Strong Buy recommendation. Looking at the underlying Component Grades to reveal specific areas of strength, Value, Momentum, and Artificial Intelligence all earn A grades, while Sentiment and Financials receive B grades. That is a powerful mix: the stock is cheap, trending strongly, and backed by solid financials and improving investor confidence. Bottom line: Petrobras has fresh operational catalysts and strong momentum without the premium valuation usually attached to a stock this hot.

🥶 NOT: Hydrogen company Plug Power (PLUG) is struggling even when its own sector catches a bid. Hydrogen stocks rallied recently, but Plug barely participated, which is a bad sign when margins remain deeply negative, cash flow is weak, and leverage keeps rising. Shares are down nearly 60% from their 52-week high and have lost almost 99% of their value since listing. For investors, the problem is that the stock still lacks evidence the business is turning.

PLUG has a Zen Rating of F, a Strong Sell recommendation. Looking at the Component Grades, Sentiment earns an F, while Value, Momentum, Financials, and Artificial Intelligence receive D grades. That combination points to weak investor confidence, poor price action, and financial stress, with little support from valuation. Bottom line: the hydrogen theme remains alive, but Plug Power still has to prove it can turn that opportunity into a viable business.

🔥 HOT: Steelmaker Nucor (NUE) has a clear catalyst in stronger domestic steel pricing and rising construction demand. Management has guided to higher earnings, while a planned $15 billion Iowa mill highlights the long-term demand picture. Add in 214 consecutive dividends, and investors are getting both cyclical upside and one of the strongest shareholder-return records in industrials. At writing, shares are up about 50% in six months but still trade below their 52-week high, while earnings are forecast to rise sharply over the next year.

NUE has a Zen Rating of A, a Strong Buy recommendation. Looking at the Component Grades, Growth, Momentum, Safety, Financials, and Artificial Intelligence all earn B grades, with Value and Sentiment at C. That is an unusually balanced profile: the business is growing, the stock is trending well, and the balance sheet remains solid without any glaring weakness. Bottom line: Nucor gives investors a strong steel-cycle catalyst backed by durable fundamentals and a long record of returning cash … No wonder it’s one of the most recent additions to our Editor-in-Chief’s hand-picked Zen Investor portfolio.

🥶 NOT: Clinical-stage biotech Viking Therapeutics (VKTX) has exciting weight-loss drug data, but the latest catalyst was dilution. The company recently raised about $500 million through stock and convertible notes, and shares fell roughly 15% on the pricing. That matters because Viking still has no revenue and projected cash burn far exceeds its available cash. Shares now trade below the recent offering price and remain well off their 52-week high. For investors, this is still a bet on future clinical success rather than an operating business today.

VKTX has a Zen Rating of F, a Strong Sell recommendation. The Component Grades reveal several weaknesses: Financials earns an F, while Growth and Artificial Intelligence receive D grades. That tells the core story: the science may be promising, but the company is financially dependent on outside capital and has yet to convert its pipeline into revenue. Bottom line: Viking may eventually deliver on the science, but right now shareholders are funding the journey.

What to Do Next?

• 77 Best Stocks NOW! >
• Options Trading with the Zen Ratings >
• 2 New Stocks to Buy from Steve Reitmeister >

Want to get in touch? Email us at news@wallstreetzen.com.